To investigate the modulation of systemic levels of soluble interleukin-6 receptor (sIL-6R) and soluble gp130 (sgp130) in untreated and treated polymyalgia rheumatica (PMR) patients during a followup period of at least 24 months in order to evaluate the relationship of these molecules with clinical outcome and their feasibility to provide a prognostic tool in clinical practice.
Serum interleukin-6 receptor in polymyalgia rheumatica: a potential marker of relapse/recurrence risk / Pulsatelli, Lia; Boiardi, Luigi; Pignotti, Elettra; Dolzani, Paolo; Silvestri, Tania; Macchioni, Pierluigi; Cantini, Fabrizio; Salvarani, Carlo; Facchini, Andrea; Meliconi, Riccardo. - In: ARTHRITIS AND RHEUMATISM. - ISSN 0004-3591. - 59:8(2008), pp. 1147-1154. [10.1002/art.23924]
Serum interleukin-6 receptor in polymyalgia rheumatica: a potential marker of relapse/recurrence risk
SALVARANI, CARLO;
2008
Abstract
To investigate the modulation of systemic levels of soluble interleukin-6 receptor (sIL-6R) and soluble gp130 (sgp130) in untreated and treated polymyalgia rheumatica (PMR) patients during a followup period of at least 24 months in order to evaluate the relationship of these molecules with clinical outcome and their feasibility to provide a prognostic tool in clinical practice.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
